Tell the FDA Why New Treatment Options Matter When promising new cancer treatments are denied approval, the impact is felt far beyond a single diagnosis. Patients with all types of cancer—melanoma, breast, lung, pancreatic, ovarian, and more—are left with fewer chances to survive and fewer ways to fight their disease. For many living with advanced cancer, standard therapies work for ... Read More| AIM at Melanoma Foundation
For AIM at Melanoma, August is all about getting ready for a busy September and fall. While August/September is Back to School for some, it’s Back to What We Do Best here at AIM. So, what have we been working on, and what is up and coming? Read on to find out! First and most importantly, researchers, patients, medical providers, ... Read More The post Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side effects that typically accompany melanoma treatments. Our goal is to explain what side effects to expect during treatment and to encourage communication with your medical team about these side effects. Side effects can range from mild to very serious, and ... Read More The post Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma appeared first ...| AIM at Melanoma Foundation
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system doesn’t see the cancer cells as foreign because the cells aren’t different enough from normal cells, and sometimes the immune system recognizes the cancer cells, but the response might not be strong enough to destroy the cancer. Immunotherapy is a treatment approach ... Read More The post New Advances in Phase 3 Treatments for Melanoma appeared fi...| AIM at Melanoma Foundation
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a treatment for advanced melanoma that had shown promise in clinical trials. RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy given in combination with nivolumab (Opdivo). RP1 + nivolumab would have been a second-line treatment for patients with advanced melanoma that did ... Read More| AIM at Melanoma Foundation
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of Brandon Blackstock from melanoma. Our sympathy goes out to his family, friends, and fans. His passing is a reminder that melanoma is a serious health threat that can affect us all. Melanoma is the most aggressive type of skin cancer, ... Read More The post Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
We’re excited to share the latest episode of the AIM at Melanoma podcast, featuring an inspiring conversation with Abby Singh, a melanoma survivor diagnosed as an Adolescent and Young Adult (AYA). Abby’s story is one of resilience, hope, and dedication—not only in her personal journey but also in her impactful work supporting cancer patients through education and nutrition. Abby’s Journey: ... Read More The post AYA Cancer Conversation: Navigating Young Adult Cancer appeared first on ...| AIM at Melanoma Foundation
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) ... Re...| AIM at Melanoma Foundation
Dear Friends, A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed encouraging results for patients who had failed first-line therapy. Read more about the denial here. Because the treatment could save lives, we feel compelled to appeal to the FDA. We need your help. Your experience with melanoma — whether you ... Read More| AIM at Melanoma Foundation
In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical role in how melanoma is diagnosed, monitored, and treated. Our latest “From the Clinic to the Living Room” webinar dives into this important and evolving topic. Hosted by Melissa Wilson, PA-C, MPAS, and featuring guest expert Yana G. Najjar, MD, ... Read More| AIM at Melanoma Foundation
Does Price Influence Sunscreen Use? A Closer Look at the Data The cost of sunscreen could be undermining proper usage, according to a recent article examining the situation. Researchers found that the cost of sunscreen is inversely proportional to the amount applied. This means that as the product cost increases, the amount applied decreases. When sunscreen is not applied properly, ... Read More| AIM at Melanoma Foundation
There may be a non-invasive option available for patients with head and neck melanoma who cannot easily receive a sentinel lymph node biopsy. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago suggested a new test could guide treatment decisions without requiring patients to undergo unnecessary surgical procedures. The test is called the Merlin Assay, ... Read More| AIM at Melanoma Foundation
Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma.| AIM at Melanoma Foundation
What is Sunscreen? Sunscreen protects the skin from absorbing ultraviolet (UV) rays. Sunscreen products contain one or more UV filters as active ingredients. There are two kinds of UV rays that can affect the skin: UVA and UVB. In the U.S., sunscreen is considered an over-the-counter drug and is regulated by the U.S. Food and Drug Administration. The preventive benefit ... Read More| AIM at Melanoma Foundation
We usually don’t feature nonmelanoma skin cancer articles here, but we thought you might be interested in what’s happening in that world. Patients with cutaneous squamous cell carcinoma treated with cemiplimab (brand name LIBTAYO) had longer disease-free survival than patients treated with a placebo. After two years, the drug was able to prevent skin cancer recurrence in the area of ... Read More| AIM at Melanoma Foundation
What is Ultraviolet Radiation? Ultraviolet (UV) radiation is a type of energy produced by the sun and by artificial sources, such as tanning beds. UV radiation is the main cause of melanoma and other skin cancers such as basal cell carcinoma and squamous cell carcinoma. The sun’s UV rays can reach a person three ways: directly from the sun; scattered ... Read More| AIM at Melanoma Foundation
